Drug Trial Radar · NCT05836948
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
174
Planned (sponsor's estimate)
Start
May 18, 2023
Primary completion
May 1, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
Conditions
- Advanced Solid Tumor
Interventions
SHR-9839Drug
Weekly fixed dose injection of SHR-9839
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) or maximum administered dose (MAD)Time frame: On the first day of each week,4 weeks is a treatment cycle
- Recommended Phase 2 dose (RP2D)Time frame: From Day 1 to 90 days after last dose
- Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0)Time frame: From Day 1 to 90 days after last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Tumor Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.